What is Novocure?
Novocure is dedicated to developing and commercializing Tumor Treating Fields (TTFields), a non-invasive therapy designed to disrupt cancer cell division. The company's commercialized products are approved in select regions for treating adult glioblastoma and malignant pleural mesothelioma. Novocure is actively exploring the efficacy of TTFields in a range of other cancers, including brain metastases, gastric cancer, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer, through extensive clinical trials. Headquartered in Jersey, with significant operations in the U.S., Germany, Switzerland, Japan, and Israel, Novocure is strategically positioned to bring its novel oncology treatments to a global patient population.
How much funding has Novocure raised?
Novocure has raised a total of $708M across 3 funding rounds:
Stock Offering
$158M
Debt
$150M
Debt
$400M
Stock Issuance/Offering (2015): $158M with participation from Undisclosed
Debt (2018): $150M led by BioPharma Credit PLC
Debt (2024): $400M supported by Pharmakon Software
Key Investors in Novocure
Pharmakon Software
Pharmakon Software GmbH is a German company specializing in omnichannel CRM and digital sales solutions for the pharmaceutical and life sciences industries, likely bringing expertise in regulatory compliance and digital engagement to their investments.
Undisclosed Investors
BioPharma Credit PLC
BioPharma Credit PLC is a credit investment fund focused on providing debt financing to the biopharmaceutical sector, suggesting a strategic financial partnership with Novocure.
What's next for Novocure?
With the recent strategic investment and a significant overall funding base of $708M, Novocure is poised for continued expansion and advancement of its TTFields therapy. The company's focus on a broad spectrum of aggressive cancers suggests a strategy aimed at establishing TTFields as a foundational treatment modality. Future developments will likely involve the progression of ongoing clinical trials, potential regulatory approvals in new indications, and the scaling of commercial operations to meet growing demand. This enterprise-level backing provides the necessary resources to fuel research and development, enhance manufacturing capabilities, and broaden market access, reinforcing Novocure's commitment to improving patient outcomes in oncology.
See full Novocure company page
